In one paragraphArticle in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Yuri TakeharaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0003-3285-4994 Yoshiaki UsuiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-6180-0704 Lenka StolařováCancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-0047-1502 Petra KleiblovaFirst Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Yusuke IwasakiLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Todd A JohnsonLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0003-3377-6692 Makoto HirataDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0002-9994-9958 Yoichiro KamataniLaboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yoshinori MurakamiDepartment of Molecular Biology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo, Japan.ORCID 0000-0002-2826-4396 Mikiko EndoLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-7292-2686 Teruhiko YoshidaDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0003-1607-3899 Amanda B SpurdleDivision of Genetics and Population Health, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0003-1337-7897 Hidewaki NakagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Libor MacurekCancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
Zdenek KleiblFirst Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic.ORCID 0000-0003-2050-9667 Yukihide MomozawaLaboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID 0000-0001-5638-3504 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
purpose
methodsTargeted sequencing and functional analyses of missense variants for the coding region of
resultsWe identified 77 gDVs including 36 functionally impaired missense variants.
conclusion
Indexed as
Checkpoint Kinase 2NeoplasmsAdultAgedAsia, EasternCase-Control StudiesFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedRisk AssessmentCheckpoint Kinase 2CHEK2 protein, human
Identifiers
PMID40893051
PMCPMC12410089
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390